SquareMind raises $18M for robotic skin imaging

SquareMind, a Paris-based medical robotics company developing dermatology imaging systems, has raised $18 million in funding as it prepares to launch Swan in the United States and Europe.

The round was led by Sonder Capital, with participation from the French government’s Deeptech 2030 Fund managed by Bpifrance, Adamed Technology, Calm/Storm Ventures and Teampact Ventures. SquareMind says the funding will support commercial, engineering and customer support hiring ahead of Swan’s near-term commercial launch.

Swan is a robotic full-body skin imaging platform designed to capture standardized dermoscopic-level images across the skin surface. The patient stands in front of the system while a robotic arm moves around the body and captures images in a short, contactless session, giving dermatologists a structured visual record that can be reviewed and compared over time.

Skin exams are high-volume, documentation-heavy and constrained by specialist availability, while lesion tracking depends on comparing small changes across visits. A system that can automate image acquisition and create a consistent full-body record sits directly inside that workflow rather than asking clinics to invent a new one.

SquareMind is also keeping the clinical role relatively clear. Swan is paired with AI-based software to support review and help track new or changing moles over time, but the company describes the physician as retaining clinical judgment. That positioning is important in medical robotics, where the commercial path is usually stronger when the system reduces routine burden before trying to replace expert decision-making.

The company says Swan is FDA-listed and CE-marked, which gives it a cleaner route into commercial dermatology settings in the United States and Europe.